Edgewise Therapeutics (EWTX) Profit After Tax (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Profit After Tax data on file, last reported at -$49.9 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 22.41% year-over-year to -$49.9 million; the trailing twelve-month figure through Mar 2026 stood at -$177.2 million (down 21.31% YoY), and the FY2025 full-year result was -$167.8 million, down 25.4% from the prior year.
• Profit After Tax climbed to -$49.9 million in Q1 2026, from -$50.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$14.7 million in Q1 2022 to a low of -$50.5 million in Q4 2025.
• A 5-year average of -$30.5 million and a median of -$28.7 million in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax sank 115.11% in 2022 and dropped 14.66% in 2025, its largest moves.
• Tracing EWTX's Profit After Tax over 5 years: stood at -$20.3 million in 2022, then slumped by 41.63% to -$28.7 million in 2023, then tumbled by 38.25% to -$39.7 million in 2024, then decreased by 27.32% to -$50.5 million in 2025, then climbed by 1.1% to -$49.9 million in 2026.
• Business Quant data shows EWTX's Profit After Tax at -$49.9 million in Q1 2026, -$50.5 million in Q4 2025, and -$40.7 million in Q3 2025.